Academic Journal
View in EDS

First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland

Bibliographic Details
Title: First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland
Authors: Simpson, C.R., Shi, T., Vasileiou, E., Katikireddi, S.V., Kerr, S., Moore, E., McCowan, C., Agrawal, U., Shah, S.A., Ritchie, L.D., Murray, J., Pan, J., Bradley, D.T., Stock, S.J., Wood, R., Chuter, A., Beggs, J., Stagg, H., Joy, M., Tsang, R.S.M., de Lusignan, S., Hobbs, R., Lyons, R.A., Torabi, F., Bedston, S., O’Leary, M., Akbari, A., McMenamin, J., Robertson, C., Sheikh, A.
Publisher Information: Nature Research
Publication Year: 2021
Collection: University of Glasgow: Enlighten - Publications
Description: Reports of ChAdOx1 vaccine–associated thrombocytopenia and vascular adverse events have led to some countries restricting its use. Using a national prospective cohort, we estimated associations between exposure to first-dose ChAdOx1 or BNT162b2 vaccination and hematological and vascular adverse events using a nested incident-matched case-control study and a confirmatory self-controlled case series (SCCS) analysis. An association was found between ChAdOx1 vaccination and idiopathic thrombocytopenic purpura (ITP) (0–27 d after vaccination; adjusted rate ratio (aRR) = 5.77, 95% confidence interval (CI), 2.41–13.83), with an estimated incidence of 1.13 (0.62–1.63) cases per 100,000 doses. An SCCS analysis confirmed that this was unlikely due to bias (RR = 1.98 (1.29–3.02)). There was also an increased risk for arterial thromboembolic events (aRR = 1.22, 1.12–1.34) 0–27 d after vaccination, with an SCCS RR of 0.97 (0.93–1.02). For hemorrhagic events 0–27 d after vaccination, the aRR was 1.48 (1.12–1.96), with an SCCS RR of 0.95 (0.82–1.11). A first dose of ChAdOx1 was found to be associated with small increased risks of ITP, with suggestive evidence of an increased risk of arterial thromboembolic and hemorrhagic events. The attenuation of effect found in the SCCS analysis means that there is the potential for overestimation of the reported results, which might indicate the presence of some residual confounding or confounding by indication. Public health authorities should inform their jurisdictions of these relatively small increased risks associated with ChAdOx1. No positive associations were seen between BNT162b2 and thrombocytopenic, thromboembolic and hemorrhagic events.
Document Type: article in journal/newspaper
File Description: text
Language: English
Relation: https://eprints.gla.ac.uk/242820/1/242820.pdf; Simpson, C.R. et al. (2021) First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland. Nature Medicine , 27(7), pp. 1290-1297. (doi:10.1038/s41591-021-01408-4 ) (PMID:34108714) (PMCID:PMC8282499)
Availability: https://eprints.gla.ac.uk/242820/
https://eprints.gla.ac.uk/242820/1/242820.pdf
Rights: cc_by_4
Accession Number: edsbas.E15867A0
Database: BASE
FullText Text:
  Availability: 0
CustomLinks:
  – Url: https://eprints.gla.ac.uk/242820/#
    Name: EDS - BASE (ns324271)
    Category: fullText
    Text: View record from BASE
Header DbId: edsbas
DbLabel: BASE
An: edsbas.E15867A0
RelevancyScore: 906
AccessLevel: 3
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 906.347900390625
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Simpson%2C+C%2ER%2E%22">Simpson, C.R.</searchLink><br /><searchLink fieldCode="AR" term="%22Shi%2C+T%2E%22">Shi, T.</searchLink><br /><searchLink fieldCode="AR" term="%22Vasileiou%2C+E%2E%22">Vasileiou, E.</searchLink><br /><searchLink fieldCode="AR" term="%22Katikireddi%2C+S%2EV%2E%22">Katikireddi, S.V.</searchLink><br /><searchLink fieldCode="AR" term="%22Kerr%2C+S%2E%22">Kerr, S.</searchLink><br /><searchLink fieldCode="AR" term="%22Moore%2C+E%2E%22">Moore, E.</searchLink><br /><searchLink fieldCode="AR" term="%22McCowan%2C+C%2E%22">McCowan, C.</searchLink><br /><searchLink fieldCode="AR" term="%22Agrawal%2C+U%2E%22">Agrawal, U.</searchLink><br /><searchLink fieldCode="AR" term="%22Shah%2C+S%2EA%2E%22">Shah, S.A.</searchLink><br /><searchLink fieldCode="AR" term="%22Ritchie%2C+L%2ED%2E%22">Ritchie, L.D.</searchLink><br /><searchLink fieldCode="AR" term="%22Murray%2C+J%2E%22">Murray, J.</searchLink><br /><searchLink fieldCode="AR" term="%22Pan%2C+J%2E%22">Pan, J.</searchLink><br /><searchLink fieldCode="AR" term="%22Bradley%2C+D%2ET%2E%22">Bradley, D.T.</searchLink><br /><searchLink fieldCode="AR" term="%22Stock%2C+S%2EJ%2E%22">Stock, S.J.</searchLink><br /><searchLink fieldCode="AR" term="%22Wood%2C+R%2E%22">Wood, R.</searchLink><br /><searchLink fieldCode="AR" term="%22Chuter%2C+A%2E%22">Chuter, A.</searchLink><br /><searchLink fieldCode="AR" term="%22Beggs%2C+J%2E%22">Beggs, J.</searchLink><br /><searchLink fieldCode="AR" term="%22Stagg%2C+H%2E%22">Stagg, H.</searchLink><br /><searchLink fieldCode="AR" term="%22Joy%2C+M%2E%22">Joy, M.</searchLink><br /><searchLink fieldCode="AR" term="%22Tsang%2C+R%2ES%2EM%2E%22">Tsang, R.S.M.</searchLink><br /><searchLink fieldCode="AR" term="%22de+Lusignan%2C+S%2E%22">de Lusignan, S.</searchLink><br /><searchLink fieldCode="AR" term="%22Hobbs%2C+R%2E%22">Hobbs, R.</searchLink><br /><searchLink fieldCode="AR" term="%22Lyons%2C+R%2EA%2E%22">Lyons, R.A.</searchLink><br /><searchLink fieldCode="AR" term="%22Torabi%2C+F%2E%22">Torabi, F.</searchLink><br /><searchLink fieldCode="AR" term="%22Bedston%2C+S%2E%22">Bedston, S.</searchLink><br /><searchLink fieldCode="AR" term="%22O%27Leary%2C+M%2E%22">O’Leary, M.</searchLink><br /><searchLink fieldCode="AR" term="%22Akbari%2C+A%2E%22">Akbari, A.</searchLink><br /><searchLink fieldCode="AR" term="%22McMenamin%2C+J%2E%22">McMenamin, J.</searchLink><br /><searchLink fieldCode="AR" term="%22Robertson%2C+C%2E%22">Robertson, C.</searchLink><br /><searchLink fieldCode="AR" term="%22Sheikh%2C+A%2E%22">Sheikh, A.</searchLink>
– Name: Publisher
  Label: Publisher Information
  Group: PubInfo
  Data: Nature Research
– Name: DatePubCY
  Label: Publication Year
  Group: Date
  Data: 2021
– Name: Subset
  Label: Collection
  Group: HoldingsInfo
  Data: University of Glasgow: Enlighten - Publications
– Name: Abstract
  Label: Description
  Group: Ab
  Data: Reports of ChAdOx1 vaccine–associated thrombocytopenia and vascular adverse events have led to some countries restricting its use. Using a national prospective cohort, we estimated associations between exposure to first-dose ChAdOx1 or BNT162b2 vaccination and hematological and vascular adverse events using a nested incident-matched case-control study and a confirmatory self-controlled case series (SCCS) analysis. An association was found between ChAdOx1 vaccination and idiopathic thrombocytopenic purpura (ITP) (0–27 d after vaccination; adjusted rate ratio (aRR) = 5.77, 95% confidence interval (CI), 2.41–13.83), with an estimated incidence of 1.13 (0.62–1.63) cases per 100,000 doses. An SCCS analysis confirmed that this was unlikely due to bias (RR = 1.98 (1.29–3.02)). There was also an increased risk for arterial thromboembolic events (aRR = 1.22, 1.12–1.34) 0–27 d after vaccination, with an SCCS RR of 0.97 (0.93–1.02). For hemorrhagic events 0–27 d after vaccination, the aRR was 1.48 (1.12–1.96), with an SCCS RR of 0.95 (0.82–1.11). A first dose of ChAdOx1 was found to be associated with small increased risks of ITP, with suggestive evidence of an increased risk of arterial thromboembolic and hemorrhagic events. The attenuation of effect found in the SCCS analysis means that there is the potential for overestimation of the reported results, which might indicate the presence of some residual confounding or confounding by indication. Public health authorities should inform their jurisdictions of these relatively small increased risks associated with ChAdOx1. No positive associations were seen between BNT162b2 and thrombocytopenic, thromboembolic and hemorrhagic events.
– Name: TypeDocument
  Label: Document Type
  Group: TypDoc
  Data: article in journal/newspaper
– Name: Format
  Label: File Description
  Group: SrcInfo
  Data: text
– Name: Language
  Label: Language
  Group: Lang
  Data: English
– Name: NoteTitleSource
  Label: Relation
  Group: SrcInfo
  Data: https://eprints.gla.ac.uk/242820/1/242820.pdf; Simpson, C.R. et al. (2021) First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland. Nature Medicine , 27(7), pp. 1290-1297. (doi:10.1038/s41591-021-01408-4 ) (PMID:34108714) (PMCID:PMC8282499)
– Name: URL
  Label: Availability
  Group: URL
  Data: https://eprints.gla.ac.uk/242820/<br />https://eprints.gla.ac.uk/242820/1/242820.pdf
– Name: Copyright
  Label: Rights
  Group: Cpyrght
  Data: cc_by_4
– Name: AN
  Label: Accession Number
  Group: ID
  Data: edsbas.E15867A0
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edsbas&AN=edsbas.E15867A0
RecordInfo BibRecord:
  BibEntity:
    Languages:
      – Text: English
    Titles:
      – TitleFull: First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Simpson, C.R.
      – PersonEntity:
          Name:
            NameFull: Shi, T.
      – PersonEntity:
          Name:
            NameFull: Vasileiou, E.
      – PersonEntity:
          Name:
            NameFull: Katikireddi, S.V.
      – PersonEntity:
          Name:
            NameFull: Kerr, S.
      – PersonEntity:
          Name:
            NameFull: Moore, E.
      – PersonEntity:
          Name:
            NameFull: McCowan, C.
      – PersonEntity:
          Name:
            NameFull: Agrawal, U.
      – PersonEntity:
          Name:
            NameFull: Shah, S.A.
      – PersonEntity:
          Name:
            NameFull: Ritchie, L.D.
      – PersonEntity:
          Name:
            NameFull: Murray, J.
      – PersonEntity:
          Name:
            NameFull: Pan, J.
      – PersonEntity:
          Name:
            NameFull: Bradley, D.T.
      – PersonEntity:
          Name:
            NameFull: Stock, S.J.
      – PersonEntity:
          Name:
            NameFull: Wood, R.
      – PersonEntity:
          Name:
            NameFull: Chuter, A.
      – PersonEntity:
          Name:
            NameFull: Beggs, J.
      – PersonEntity:
          Name:
            NameFull: Stagg, H.
      – PersonEntity:
          Name:
            NameFull: Joy, M.
      – PersonEntity:
          Name:
            NameFull: Tsang, R.S.M.
      – PersonEntity:
          Name:
            NameFull: de Lusignan, S.
      – PersonEntity:
          Name:
            NameFull: Hobbs, R.
      – PersonEntity:
          Name:
            NameFull: Lyons, R.A.
      – PersonEntity:
          Name:
            NameFull: Torabi, F.
      – PersonEntity:
          Name:
            NameFull: Bedston, S.
      – PersonEntity:
          Name:
            NameFull: O’Leary, M.
      – PersonEntity:
          Name:
            NameFull: Akbari, A.
      – PersonEntity:
          Name:
            NameFull: McMenamin, J.
      – PersonEntity:
          Name:
            NameFull: Robertson, C.
      – PersonEntity:
          Name:
            NameFull: Sheikh, A.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 01
              Type: published
              Y: 2021
          Identifiers:
            – Type: issn-locals
              Value: edsbas
            – Type: issn-locals
              Value: edsbas.oa
ResultId 1